The gene BTN2A1 (butyrophilin subfamily 2 member A1) is mapped to human chromosome 6p22.1. It is ubiquitously expressed. BTN2A1 is an MHC (major histocompatibility complex)-encoded cell surface glycoprotein.
Synonyms: Anti-BT2.1; Anti-BTF1; Anti-BTN2.1
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: BTN2A1 (butyrophilin subfamily 2 member A1) is suggested to have roles in lipid, fatty acid, and sterol metabolism. Polymorphisms in BTN2A1 are linked with dyslipidemia, myocardial infarction, type 2 diabetes mellitus, chronic kidney disease and hypertension.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC